Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dystrophin is a tumor suppressor in human cancers with myogenic programs.

Nature genetics - 1 Jun 2014

Wang Yuexiang, Marino-Enriquez Adrian, Bennett Richard R, Zhu Meijun, Shen Yiping, Eilers Grant, Lee Jen-Chieh, Henze Joern, Fletcher Benjamin S, Gu Zhizhan, Fox Edward A, Antonescu Cristina R, Fletcher Christopher D M, Guo Xiangqian, Raut Chandrajit P, Demetri George D, van de Rijn Matt, Ordog Tamas, Kunkel Louis M, Fletcher Jonathan A

Abstract excerpt

Many common human mesenchymal tumors, including gastrointestinal stromal tumor (GIST), rhabdomyosarcoma (RMS) and leiomyosarcoma (LMS), feature myogenic differentiation. Here we report that intragenic deletion of the dystrophin-encoding and muscular dystrophy-associated DMD gene is a frequent mechanism by which myogenic tumors progress to high-grade, lethal sarcomas. Dystrophin is expressed in the non-neoplastic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Dystrophin
Share to Gastrointestinal Stromal Tumors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, Tumor Suppressor

Share to Leiomyosarcoma

Share to Muscle Development

Share to Muscular Dystrophies

Share to Rhabdomyosarcoma

Share to Sarcoma

Source

Open in PubMed Open full text

Identifiers

PMID: 24793134
DOI: 10.1038/ng.2974
PMCID: PMC4225780

Genes

DMD

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dystrophin is a tumor suppressor in human cancers with myogenic programs.PMID 24793134Read ↗

Non-myogenic tumors display altered expression of dystrophin (DMD) and a high frequency of genetic alterations.Semantic proximity Read ↗

Downregulation of dystrophin expression occurs across diverse tumors, correlates with the age of onset, staging and reduced survival of patientsSemantic proximity Read ↗

MyoD-Cre driven alterations in K-Ras and p53 lead to a mouse model with histological and molecular characteristics of human rhabdomyosarcoma with direct translational applicationsSemantic proximity Read ↗

Mice lacking dystrophin or alpha sarcoglycan spontaneously develop embryonal rhabdomyosarcoma with cancer-associated p53 mutations and alternatively spliced or mutant Mdm2 transcripts.Semantic proximity Read ↗

Lineage-defined leiomyosarcoma subtypes emerge years before diagnosis and determine patient survival.Semantic proximity Read ↗

Muscle Stem Cells Give Rise to Rhabdomyosarcomas in a Severe Mouse Model of Duchenne Muscular DystrophySemantic proximity Read ↗

A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations.Semantic proximity Read ↗

DNA damage, somatic aneuploidy, and malignant sarcoma susceptibility in muscular dystrophies.Semantic proximity Read ↗

Transactivating mutation of the MYOD1 gene is a frequent event in adult spindle cell rhabdomyosarcoma.Semantic proximity Read ↗

MicroRNAs in rhabdomyosarcoma: pathogenetic implications and translational potentialitySemantic proximity Read ↗

Deep Sequencing the microRNA profile in rhabdomyosarcoma reveals down-regulation of miR-378 family membersSemantic proximity Read ↗

Probing for a deeper understanding of rhabdomyosarcoma: insights from complementary model systems.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.